Feasibility of high-dose interleukin-2 in heavily pretreated pediatric cancer patients

Annals of Oncology

Volumn 16, Issue 7, 2005, Pages 1199-1206

  Schwinger, Wolfgang ^a   Klass, V ^a   Benesch, M ^a   Lackner, H ^a   Dornbusch, H J ^a   Sovinz, P ^a   Moser, A ^a   Schwantzer, G ^a   Urban, C ^a  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

Author keywords

Cancer; Children; Interleukin 2; Side effects; Toxicity

Indexed keywords

ALBUMIN; ALKALINE PHOSPHATASE; ANTINEOPLASTIC AGENT; C REACTIVE PROTEIN; CHOLINESTERASE; CREATINE; GAMMA GLUTAMYLTRANSFERASE; GLUCOSE; PROTEIN; RECOMBINANT INTERLEUKIN 2; INTERLEUKIN 2;

ACUTE KIDNEY FAILURE; ADOLESCENT; ADULT; ADVANCED CANCER; ANEMIA; ANOREXIA; ARTICLE; BLOOD TOXICITY; BODY WEIGHT; BONE PAIN; CAPILLARY LEAK SYNDROME; CARDIOTOXICITY; CHILD; CHILDHOOD CANCER; CLINICAL ARTICLE; CLINICAL TRIAL; CREATININE BLOOD LEVEL; DIARRHEA; DISEASE SEVERITY; DRUG MEGADOSE; ENZYME ASSAY; EWING SARCOMA; FATIGUE; FEASIBILITY STUDY; FEMALE; FEVER; FLU LIKE SYNDROME; GASTROINTESTINAL TOXICITY; HEADACHE; HUMAN; HYPOTENSION; LEUKOCYTE COUNT; LEUKOCYTOSIS; MALE; METASTASIS; MYALGIA; NAUSEA; NEPHROBLASTOMA; NEPHROTOXICITY; NEUROBLASTOMA; OSTEOSARCOMA; PRIORITY JOURNAL; PROGNOSIS; PRURITUS; QUALITY OF LIFE; SIDE EFFECT; SOLID TUMOR; TACHYCARDIA; THROMBOCYTOPENIA; VOMITING; CLASSIFICATION; DOSE RESPONSE; NEOPLASM; PRESCHOOL CHILD;

ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEASIBILITY STUDIES; FEMALE; HUMANS; INTERLEUKIN-2; MALE; NEOPLASMS;

EID: 25444441051     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdi226     Document Type: Article

References (28)

1. Wang HM, Smith KA. The interleukin 2 receptor. Functional consequences of its bimolecular structure. J Exp Med 1987; 166: 1055-1069.
2. Stern JB, Smith KA. Interleukin-2 induction of T-cell G1 progression and c-myb expression. Science 1986; 233: 203-206.
3. Yang SC, Grimm EA, Parkinson DR et al. Clinical and immunomodulatory effects of combination immunotherapy with low-dose interleukin 2 and tumor necrosis factor alpha in patients with advanced non-small cell lung cancer: A phase I trial. Cancer Res 1991; 5: 3669-3676.
4. Yang SC, Owen-Schaub L, Grimm EA, Roth JA. Induction of lymphokine-activated killer cytotoxicity with interleukin-2 and tumor necrosis factor-alpha against primary lung cancer targets. Cancer Immunol Immunother 1989; 29: 193-198.
5. Grimm EA, Mazumder A, Zhang HZ, Rosenberg SA. Lymphokine activated killer cell phenomenon. Lysis of natural killer resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes. J Exp Med 1982; 155: 1823-1841.
6. Mier JW, Vachino G, van der Meer JW et al. Induction of circulating tumor necrosis factor (TNF alpha) as the mechanism for the febrile response to interleukin-2 (IL-2) in cancer patients. J Clin Immunol 1988; 8: 426-436.
7. Owen-Schaub LB, de Mars M, Murphy EC Jr, Grimm EA. IL-2 dose regulates TNF-alpha mRNA transcription and protein secretion in human peripheral blood lymphocytes. Cell Immunol 1991; 132: 193-200.
8. Oppenheim MH, Lotze MT. Interleukin-2: Solid-tumor therapy. Oncology 1994; 51: 154-169.
9. Tester WJ, Kim KM, Krigel RL et al. A randomized phase II study of interleukin-2 with and without beta-interferon for patients with advanced non-small cell lung cancer: An Eastern Cooperative Oncology Group study. Lung Cancer 1999; 25: 199-206.
10. Mantovani G, Maccio A, Mulas C et al. Dose-intense phase II study of weekly cisplatin and epidoxorubicin plus medroxyprogesterone acetate and recombinant interleukin 2 in stage IIIB-IV non-small cell lung cancer. Oncol Rep 2002; 9: 661-670.
11. Krastev Z, Koltchakov V, Tomov B, Koten JW. Non-melanoma and non-renal cell carcinoma malignancies treated with interleukin-2. Hepatogastroenterology 2003; 50: 1006-1016.
12. Dilloo D, Laws HJ, Hanenberg H et al. Induction of two distinct natural killer-cell populations, activated T cells and antineoplastic cytokines, by interleukin-2 therapy in children with solid tumours. Exp Hematol 1994; 22: 1081-1088.
13. Kalwak K, Ussowicz M, Gorczynska E et al. Immunologic effects of intermediate-dose IL-2 i.v. after autologous hematopoietic cell transplantation in pediatric solid tumours. J Interferon Cytokine Res 2003; 23: 173-181.
14. Bauer M, Reaman GH, Hank JA et al. A phase II trial of human recombinant interleukin-2 administered as a 4-day continuous infusion for children with refractory neuroblastoma, non-Hodgkin's lymphoma, sarcoma, renal cell carcinoma, and malignant melanoma. A Children's Cancer Group study. Cancer 1995; 75: 2959-2965.
15. Schwartz RN, Stover L, Dutcher J. Managing toxicities of high-dose interleukin-2. Oncology 2002; 16 (11 Suppl 13): 11-22.
16. Sievers EL, Lange BJ, Sondel PM et al. Feasibility, toxicity, and biologic response of interleukin-2 after consolidation chemotherapy for acute myelogenous leukemia: A report from the Children's Cancer Group. J Clin Oncol 1998; 16: 914-919.
17. Siegel JP, Puri RK. Interleukin-2 toxicity. J Clin Oncol 1991; 9: 694-704.
18. Baluna R, Vitetta ES. Vascular leak syndrome: A side effect of immunotherapy. Immunopharmacology 1997; 37: 117-132.
19. Lissoni P, Barni S, Cattaneo G et al. Activation of the complement system during immunotherapy of cancer with interleukin-2: A possible explanation of the capillary leak syndrome. Int J Biol Markers 1990; 5: 195-207.
20. Glauser FL, DeBlois G, Bechard D et al. Cardiopulmonary toxicity of adoptive immunotherapy. Am J Med Sci 1988; 296: 406-412.
21. Vespasiani Gentilucci U, Santini D et al. Liver cirrhosis after prolonged therapy with IFN-alpha plus interleukin-2 in a metastatic renal cancer long-term survivor. J Interferon Cytokine Res 2002; 22: 683-688.
22. Guleria AS, Yang JC, Topalian SL et al. Renal dysfunction associated with the administration of high-dose interleukin-2 in 199 consecutive patients with metastatic melanoma or renal carcinoma. J Clin Oncol 1994; 12: 2714-2722.
23. White RL, Schwartzentruber DJ, Guleria A et al. Cardiopulmonary toxicity of treatment with high-dose interleukin-2 in 199 consecutive patients with metastatic melanoma or renal cell carcinoma. Cancer 1994; 74: 3212-3222.
24. Bonig H, Laws HJ, Wundes A et al. In vivo cytokine responses to interleukin-2 immunotherapy after autologous stem cell transplantation in children with solid tumors. Bone Marrow Transplant 2000; 26: 91-96.
25. Rosenberg SA, Lotze MT, Muul LM et al. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med 1987; 316: 889-897.
26. Rosenberg SA, Lotze MT, Yang JC et al. Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients. Ann Surg 1989; 210: 474-485.
27. Margolin KA, Rayner AA, Hawkins MJ et al. Interleukin-2 and lymphokine-activated killer cell therapy of solid tumors: Analysis of toxicity and management guidelines. J Clin Oncol 1989; 7: 486-498.
28. Negrier S, Michon J, Floret D et al. Interleukin-2 and lymphokine-activated killer cells in 15 children with advanced metastatic neuroblastoma [published erratum appears in J Clin Oncol 1992; 10: 1026]. J Clin Oncol 1991; 9: 1363-1370.